印度尼西亚重型地中海贫血脾切除患者的肺炎球菌疫苗接种
本研究评估重型地中海贫血脾切除患者接种PCV和PPV后的肺炎球菌IgG水平,以及补锌对特异性免疫应答的影响。患者先接种PCV(Prevenar 13®),随机分为锌组和安慰剂组,8周后接种PPV(Pneumovax®),锌组补锌1.5mg/kg/天(最大50mg/天)。结果显示接种PPV前后肺炎球菌IgG升高两组无差异,补锌对肺炎球菌IgG发展也无差异。
要点
- 重型地中海贫血脾切除患者接种PCV后8周接种PPV,肺炎球菌IgG升高两组无差异(p=0.642和p=0.528)。
- 补锌(1.5mg/kg/天,最大50mg/天)对肺炎球菌IgG发展无差异。
- 无PPV组锌组中位IgG从315升至1812.5 mU/mL,安慰剂组从338.5升至2857.5 mU/mL。
核心结论
- 重型地中海贫血脾切除患者接种PPV前后肺炎球菌IgG升高无差异。
- 补锌对肺炎球菌IgG发展无差异。
研究设计与样本
- 重型地中海贫血脾切除患者先接种PCV(Prevenar 13®),随机分为锌组和安慰剂组,8周后接种PPV(Pneumovax®)。
- 锌组补锌1.5mg/kg/天(最大50mg/天)。
- 肺炎球菌IgG在试验开始时和12周后检测。
主要发现
- 无PPV组:锌组中位初始IgG 315(范围65-1419)mU/mL,安慰剂组338.5(范围82-1648)mU/mL;锌组中位最终IgG 1812.5(范围834-2444)mU/mL,安慰剂组2857.5(范围834-2624)mU/mL;两组升高比较p=0.642。
- 有PPV组:锌组中位初始IgG 1333(范围793-2031)mU/mL,安慰剂组880(范围74-1686)mU/mL;锌组中位最终IgG 1487(范围635-1757)mU/mL,安慰剂组1012(范围292-1732)mU/mL;两组升高比较p=0.528。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Streptococcus pneumoniae is a capsulated bacterium that can cause severe infection in patients with thalassemia major, particularly those who have undergone splenectomy. The absence of the spleen as well as zinc deficiency in splenectomized patients with thalassemia major increases the possibility of developing invasive pneumococcal infection. The aims of this study are to evaluate pneumococcal IgG levels following PCV and PPV immunizations and the effect of zinc supplementation on qualitative specific immune responses in splenectomized patients with thalassemia. METHODS: Splenectomized patients with thalassemia major were administered a PCV pneumococcal vaccine (Prevenar 13®) at the start of the trial, after which they were randomly assigned to 2 groups (zinc and placebo group). After 8weeks, the patients received a PPV pneumococcal vaccine (Pneumovax®). Zinc syrup was provided to the zinc group at a dose of 1.5mg/kg/day (maximum of 50mg/day). Pneumococcal IgG examinations were conducted at the start of the trial and after 12weeks. RESULTS: In the group without PPV, the median initial pneumococcal IgG value was 315 (ranging from 65 to 1419) mU/mL for the zinc group and 338.5 (ranging from 82 to 1648) mU/mL for the placebo group. The median final pneumococcal IgG value was 1812.5 (ranging from 834 to 2444) mU/mL for the zinc group and 2857.5 (ranging from 834 to 2624) for the placebo group. The increase in the pneumococcal IgG value between the two groups was comparable (p=0.642). In the group with previous PPV, the median initial pneumococcal IgG value was 1333 (ranging from 793 to 2031) mU/mL for the zinc group and 880 (ranging from 74 to 1686) mU/mL for the placebo group. The median final pneumococcal IgG value was 1487 (ranging from 635 to 1757) mU/mL for the zinc group and 1012 (ranging from 292 to 1732) mU/mL for the placebo group. The increase in the pneumococcal IgG value between the two groups was comparable (p=0.528). CONCLUSION: There is no difference in the increase in pneumococcal IgG level in splenectomized patients with thalassemia major prior to and after receiving PPV. There were no differences observed in the development of pneumococcal IgG following zinc supplementation.
引用
- Sari TT, Akib AAP, Gatot D, et al. Pneumococcal vaccination for splenectomized patients with thalassemia major in Indonesia. Vaccine. 2017. PMID: 28712490. doi:10.1016/j.vaccine.2017.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。